High-Density Lipoprotein Nanoparticle Imaging in Atherosclerotic Vascular Disease

Mass Spectrometry-Based Proteomic Study Makes High-Density Lipoprotein a Biomarker for Atherosclerotic Vascular Disease

High-density lipoprotein (HDL) is a lipid and protein complex that consists of apolipoproteins and lower level HDL-associated enzymes. HDL dysfunction is a factor in atherosclerosis and decreases patient survival. Mass spectrometry- (MS-) based proteomics provides a high throughput approach for analyzing the composition and modifications of complex HDL proteins in diseases. HDL can be separated...

A Statin-Loaded Reconstituted High-Density Lipoprotein Nanoparticle Inhibits Atherosclerotic Plaque Inflammation

Inflammation is a key feature of atherosclerosis and a target for therapy. Statins have potent anti-inflammatory properties but these cannot be fully exploited with oral statin therapy due to low systemic bioavailability. Here we present an injectable reconstituted high-density lipoprotein (rHDL) nanoparticle carrier vehicle that delivers statins to atherosclerotic plaques. We demonstrate the a...

High-density lipoprotein is a nanoparticle, but not all nanoparticles are high-density lipoprotein.

High-density lipoprotein, low-density lipoprotein, and coronary heart disease.

High-density lipoprotein and the dynamics of atherosclerotic lesions.

Plump et al 1 reported in 1994 that the expression of a human transgene for apoA-I, the major apolipoprotein of HDL, in apoE knockout mice dramatically reduced lesion formation. In the present issue of Circulation, Rong et al2 demonstrate that the composition and structure of advanced atherosclerotic plaques can be significantly altered by the expression of this same transgene. Rong and colleag...